Showing 651-660 of 725 results for "".
- LEO Pharma Submits NDA for Aerosol Foam for Psoriasis to FDAhttps://practicaldermatology.com/news/leo-pharma-submits-nda-for-aerosol-foam-for-psoriasis-to-fda/2459033/LEO Pharma has submitted a New Drug Application to FDA for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the treatment of psoriasis vulgaris. The novel aerosol foam formulation of the fixed combination calcipotriene/betamethasone dipropionate has been developed w
- Advanced Dermatology & Cosmetic Surgery, (ADCS Clinics) Acquires Lakeland Dermatology, Inc.https://practicaldermatology.com/news/20130906-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_lakeland_dermatology_inc/2459467/ADCS Clinics (“ADCS”) has completed the acquisition of Dr. David W. Murray's, dermatology practice located in Lakeland, Florida. Dr. Murray is Board-Certified - trained at the University of Oregon Health Sciences Center and did his residency at the Naval Hospital in San Diego. He spent 11 years in a
- Modern Aesthetics Launches from Bryn Mawr Communicationshttps://practicaldermatology.com/news/20130228-modern_aesthetics_launches_from_bryn_mawr_communications/2459603/The debut issue of Modern Aesthetics (www.modernaesthetics.com), a publication dedicated to coverage of minimally invasive cosmetic procedures and targeting Plastic Surgeons, Facial Plastic Surgeons, Oculoplastic Surgeons, and Dermatologists, has been released by Bryn Mawr Communications III, LLC. W
- Valeant Acquires Medicis Pharmaceutical Corp. for $2.6 Billionhttps://practicaldermatology.com/news/20120904-valeant_acquires_medicis_pharmaceutical_for_26_billion/2459743/Valeant Pharmaceuticals announced an agreement to acquire Medicis Pharmaceutical for $44 per share in cash, in a deal worth approximately $2.6 billion. The transaction is expected to close in the first half of 2013 and has been approved by each company's board of directors. The combined operations w
- National Rosacea Society to Host 20th Anniversary Galahttps://practicaldermatology.com/news/20120730-national_rosacea_society_to_host_20th_anniversary_gala/2459759/The National Rosacea Society is hosting a 20th Anniversary Gala Celebration and Dinner on August 17, 2012, from 6-9pm at the Boston Sheraton Hotel during the summer AAD meeting to give thanks to the countless healthcare professionals who have helped improve the quality of life for rosacea patients w
- OPTiM Trial for T-VEC in Unresectable Melanomahttps://practicaldermatology.com/news/20120604-optim_trial_for_t-vec_in_unresectable_melanoma/2459791/The OPTiM trial for T-VEC (formerly OncoVEXGM-CSF), an oncolytic HSV1 that selectively replicates in tumors, is now underway, according to a presentation by Kaufman, et al. at ASCO 2012. The randomized phase 3 trial will evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared w
- Sarecycline Monotherapy Delivers in Real-World Acne Studyhttps://practicaldermatology.com/news/sarecycline-monotherapy-delivers-in-real-world-acne-study/2484121/A post hoc analysis of the PROSES study found that oral sarecycline monotherapy is as effective as combination therapy with topicals in treating moderate-to-severe acne vulgaris (AV), based on 12-week outcomes from a real-world U.S. cohort presented by Dr. Hilary B
- NB-UVB Phototherapy Effective for Psoriasis in Skin of Colorhttps://practicaldermatology.com/news/nb-uvb-phototherapy-effective-for-psoriasis-in-skin-of-color/2483263/A new systematic review and meta-analysis confirms that narrowband ultraviolet B (NB-UVB) phototherapy is effective for psoriasis in patients with skin of color, underscoring its role as a valuable treatment option despite the widespread adoption of biologics and systemic agents.
- Study: Ultralow-Dose Rituximab Effective in Pemphigushttps://practicaldermatology.com/news/study-ultralow-dose-rituximab-effective-in-pemphigus/2474602/A new 52-week clinical trial found that ultralow-dose rituximab (ULRTX) achieved comparable efficacy, safety, and B-cell depletion to standard and low-dose regimens in patients with moderate-to-severe pemphigus vulgaris (PV) and pemphigus foliaceus (PF).
- VYNE Therapeutics Completes Enrollment for Phase 2b Trial of VYN201 in Nonsegmental Vitiligohttps://practicaldermatology.com/news/vyne-therapeutics-completes-enrollment-phase-2b-trial-vyn201-nonsegmental-vitiligo/2470854/VYNE Therapeutics Inc. has finalized enrollment for its Phase 2b trial of VYN201, a once-daily topical gel for nonsegmental vitiligo, with initial data from the 24-week double-blind portion anticipated in mid-2025, according to a news release from the manufacturer. The randomized, double-b